Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Takayuki Shimose

Survival Analysis for Patients With ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated With Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Oncologist

English

Exploration of Resistance Mechanisms for EGFR-TKIs Based on Plasma Analysis by Digital PCR and Next-Generation Sequencing

English

Related publications

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology

English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

Oncology

2016

English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy

Oncology

Pharmacology

2019

English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

English

Case Report of Non-Small Cell Lung Cancer With STRN-ALK Translocation: A Nonresponder to Alectinib

Journal of Nihon University Medical Association

2019

English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer

English

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Therapeutic Advances in Medical Oncology

Oncology

2015

English

Fever and Survival With Drug-Treated Non-Small Cell Lung Cancer.

Kurume Medical Journal

Medicine

2001

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Takayuki Shimose

Survival Analysis for Patients With ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated With Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Exploration of Resistance Mechanisms for EGFR-TKIs Based on Plasma Analysis by Digital PCR and Next-Generation Sequencing

Related publications

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Case Report of Non-Small Cell Lung Cancer With STRN-ALK Translocation: A Nonresponder to Alectinib

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Fever and Survival With Drug-Treated Non-Small Cell Lung Cancer.